Citigroup Raises Danaher (DHR) Price Target to $270
Key Points
- Citigroup reiterated its Buy rating on Danaher Corporation on October 22, 2026, while boosting its price target to $270.00 from $230.00.
- Citigroup's $270 price target implies 17.52% upside from Danaher Corporation's ($DHR) current $229.74 share price.
- Danaher Corporation recently traded near $229.74, sitting well above its 200-day moving average of $201.26.
- Capital International Investors held 15,504,420 shares valued at about $3.56 billion after growing its position.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Citigroup reiterated its Buy rating on Danaher Corporation DHR on October 22, 2026, while pushing its price target up from $230.00 to $270.00. The note reflects confidence in the healthcare company's ongoing health and market position.
DHR
Danaher Corporation
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Citigroup's Call on Danaher Corporation
On October 22, 2026, Citigroup maintained its Buy rating on the stock and adjusted its target higher to $270.00 from $230.00. Several other firms also updated their outlooks on the same day, including Barclays keeping an Overweight rating with a $260.00 target, JP Morgan maintaining Overweight with a $270.00 target, TD Cowen reiterating a Buy rating with a $270.00 target, and Stifel keeping a Buy rating while lifting its target to $260.00 from $220.00. Wall Street currently maintains a consensus strong buy rating on the shares with an average price target of $247.18 across 22 analyst opinions.
Other Institutional Activity in Danaher Corporation
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3.56 billion in its report for the period ending June 30, 2026.
Danaher Corporation Stock Up 2.5%
Danaher Corporation recently traded around $229.74 on October 22, 2026, compared to an event close of $229.75. The stock trades about 14.2% above its 200-day moving average of $201.26 and sits roughly 5.4% below its 52-week high of $242.80.
$DHR price target
Danaher Corporation daily closes and this analyst's $270 target. Not advice.
Recent Earnings
Danaher Corporation reported trailing twelve month revenue of $25.11 billion and earnings of $6.04 per share. The company posted a net profit margin of 15.9% and a return on equity of 7.6% alongside a year-over-year revenue growth rate of 5.5%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher Corporation pays an annual dividend rate of $1.60 per share, giving it a dividend yield of 0.71% based on a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Director Alan G Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Later, Chief Executive Officer Rainer M Blair disposed of 58,255 shares on August 21, 2026, valued at approximately $12.74 million.
About Danaher Corporation
Headquartered in Washington, DC, Danaher Corporation designs and manufactures professional, medical, research, and industrial products and services. The company operates through three core segments focused on biotechnology, life sciences, and diagnostics, supporting healthcare providers and research institutions worldwide.
Bottom Line
Investors will continue monitoring analyst revisions and upcoming earnings reports to gauge whether the healthcare leader can reach the new price targets set across Wall Street. No specific investment advice is implied by these ratings.
Related Filing Alerts
Source: Citigroup's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts